On Sunday, the Cairo-based 85-year-old Egyptian pharmaceutical industry mogul, Eva Pharma Pharmaceutical Industries had issued a statement saying that the pharmaceutical had reached an accord with the American biopharmaceutical Gilead Sciences, which holds the patent to a potential cure of the ongoing pandemic outbreak, Remdesivir, initially created to battle against the Ebola virus, to manufacture and distribute its pandemic drug in 127 countries across the globe.
In point of fact, latest announcement from the Cairo-based pharmaceutical company came forth weeks after the Gilead Science Inc.’s Remdesivir had shown significant improvement in decreasing the timeframe of hospital stay for the pandemic affected patients, while according to its human trial report, the pandemic patients who had taken Remdesivir, had witnessed a decline of average hospital stay of 8 days compared to an average of 11 to 12 days in the pandemic affected patients who did not take the Remdesivir.
However, in case of critically ill patients, the drug showed little or no response at all, a research study had revealed later last month, though another clinical trial of Remdesivir on monkeys revealed later last month that the Gilead Sciences’ pandemic drug could prevent the development of pneumonia in the pandemic patients, but had shown little response on a severely infected lung.
Nonetheless, despite lack of concrete evidences that the Gilead Sciences Inc.’s Remdesivir could act as a potential cure for the critically ill pandemic patients, a number of countries including the United States, India, South Korea alongside a few countries in the bloc had authorized the use of drug in critically ill patients.
Eva to enhance the schedule of Remdesivir production as Egyptian pandemic cases spike
Meanwhile, referring to the agreement reached with the US-based pharmaceutical, Eva said on later part of the day, “The Egyptian company will have all the technological methods, specifications of the manufacturing process and the methods of the American company in order to enhance the schedule for the production of Remdesivir as soon as possible. ”